Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

>Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients

 

PARIS, August 30, 2010 /PRNewswire-FirstCall/ --

- First Results From the TEMSO Phase III Trial to be Presented During the ECTRIMS Congress in October 2010

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial. Both the 7mg and 14mg doses of teriflunomide were well tolerated with a similar number of patients reporting either treatment-emergent adverse events (TEAEs) or TEAEs leading to treatment discontinuation in the treatment arms versus placebo.

Effects on other clinical and MRI related outcomes further support the primary outcome. The safety profile was in line with previous clinical experience.

The TEMSO trial is the first study of a large phase III clinical development program to produce results on teriflunomide as monotherapy. Study findings from TEMSO will be presented during the platform presentation scheduled for October 15, 2010, starting at 9:15 a.m. CET at the 26th Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden. The TEMSO study results are embargoed until this oral presentation
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... companies release latest developments, patents and results of studies ... GNSZ), Eli Lilly and Company (NYSE: LLY ... Celgene Corporation (NASDAQ: CELG ) and Arena ... GNSZ), a leader in developing prodrug therapeutics for the ...
(Date:9/19/2014)... 2014 , The first grants ... Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative ... in the field of growth  , EMD ... Germany , today announced the first recipients of ... awards were announced during a Satellite Symposium organized by ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... , , CLEVELAND, Sept. 9 ... for ways to drive out costs and inefficiencies. Because it,s proven ... documents that go along with them, many are turning to enterprise ... the roadblock: budgets are tighter than ever, so how do these ...
... , , THE WOODLANDS, Texas, Sept. ... LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments ... Ph.D. , Lexicon,s president and chief executive officer, will present at ... in New York, New York on Tuesday, September 15, 2009 at 1:35 ...
... BRIDGEWATER, England, September 9 Clinical Therapeutics,(, http://www.clinicaltherapeutics.com/ ... announce the addition of Michael G. Spigarelli, MD, ... As section editor for the Pediatric, ... the,Pediatric Research section), Dr. Spigarelli brings a wealth ...
Cached Biology Technology:Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 2Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 3Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 4Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section 2
(Date:9/19/2014)... species which over thousands of years has adapted to the ... that makes the cold dangerous for you. , This is ... and the cold provoking substance, called nonylphenol, comes from the ... suspected of being a endocrine disruptor, but when entering the ... ability to protect the cells in its body from cold ...
(Date:9/18/2014)... Boulder, Colo., USA A new GSA Bulletin ... along the lower Rio Puerco and Chaco Wash in ... tree rings from salt cedar and willow, investigators were ... thick or greater. They then combined this data with ... reconstruct the history of these arroyos. , Arroyos are ...
(Date:9/18/2014)... A novel robotic system that can operate inside the ... as part of a biomedical research partnership program at ... of determining if the robot, in conjunction with real-time ... accurate, less costly, and less discomforting for the patient. ... prostate cancer therapies with greater precision. , Developed by ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... the Sundarbans, resulting in as much as 200m of coast ... (11th Jan) in Remote Sensing by scientists from ... development thrives, and global temperature continues to rise, natural protection ... rates. This will inevitably lead to species loss in this ...
... W. Finberg, MD, the Richard M. Haidack Professor of ... University of Massachusetts Medical School, is lead investigator on ... predicting how the influenza virus changes and evolves in ... This approach has promise for becoming a pivotal tool ...
... cells can be grown on biocompatible scaffolds to form ... repair and regeneration of damaged or diseased tissue. However, ... a specific pattern or alignment. An innovative method for ... tissue architectures is described in an article in ...
Cached Biology News:Bengali forests are fading away 2
...
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
Human Glypican 2 Biotinylated Affinity Purified PAb...
Biology Products: